Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 16/20 | 0.64 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.49 |
| ▸ | EPHX1 | P07099 | 2/20 | 0.48 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.48 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.48 |
| ▸ | LIPE | Q05469 | 1/20 | 0.46 |
| ▸ | ACHE | P22303 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28885269 | 1.00 | EPHX2 (0.64) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL23389248 | 0.90 | EPHX2 (0.61) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL25987957 | 0.89 | EPHX2 (0.64) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL25987958 | 0.87 | EPHX2 (0.62) | EPHX2POLBSCN9ACYP2C9CYP2C19 | |
| SCHEMBL23389093 | 0.86 | EPHX2 (0.61) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL23389102 | 0.83 | EPHX2 (0.64) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL25987740 | 0.83 | EPHX2 (0.64) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL23419215 | 0.83 | EPHX2 (0.63) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL23418851 | 0.83 | EPHX2 (0.63) | EPHX2POLBSCN9AEPHX1CYP2C9 | |
| SCHEMBL23389242 | 0.83 | EPHX2 (0.56) | EPHX2POLBSCN9AEPHX1CYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | SHANGPHARMA INNOVATION INC. | 2025-08-21 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | UNIV CALIFORNIA (US) | 2023-06-29 | — | — | US | disclosed |
| CN-115335039-A | Caspase 6 inhibitors and uses thereof | 加利福尼亚大学董事会 | 2022-11-11 | — | — | CN | disclosed |
| EP-4061341-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | The Regents of the University of California (US) | 2022-09-28 | — | — | EP | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
| WO-2021102361-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2021-05-27 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230202974-A1 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | EPHX2 3551/4885POLB 4066/4885SCN9A 3345/4885 |
| US-20250263366-A2 | CASPASE 6 INHIBITORS AND USES THEREOF | CASP6, CASP1, CASP10 | EPHX2 3551/4885POLB 4066/4885SCN9A 3345/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.